INTRODUCTION
Follow-up studies of epilepsy in learning disabilities are few in number. Of the available studies most are of the prognosis for children with epilepsy and learning disabilities'q2, reports of the effects of drug alteration3-" or follow-up studies of mortality"-'3.
Studies of prognosis for children with epilepsy and learning disabilities have generally reflected a positive outcome. Goulden et al. ' reported that by the age of 22 years 39% had achieved 5 years free of seizures and that this performance varied according to the nature and cause of the learning disabilities. Brorson and Wranne* studied children aged O-19 years who had active epilepsy in a defined Swedish population. Their 12-year follow-up showed long-standing remission occurring in 124 of the 194 children with abnormal neurology and/or learning disabilities. Similar cohort studies of adults with learning disabilities are not available, although studies of the non-learning disabled population with epilepsy would suggest that many should achieve remission from seizurest4.
There have been numerous studies that report the effects of drug alterations involving people with leaming disabilities and epilepsy. These studies have generally aimed to reduce polypharmacy of antiepileptic drugs, withdraw antiepileptic drugs or change to newer medicines. The results achieved by Pellock and Hunt3 are typical. They showed a 19% reduction of polypharmacy, a 12.7% rate of discontinuation and reduction of the use of barbiturates. Interestingly, half of those who discontinued antiepileptic drug treatment required its reinstatement.
The follow-up studies of mortality have generally demonstrated that epilepsy is associated with significantly increased mortality in persons with learning disabilities. Fosgren et al. 1 ' also showed that increased mortality is related to seizure type and frequency but that the cause of death was seldom directly related to the seizures.
Most studies of epilepsy in learning disabilities indicate that the first seizures usually occur in the first 5 years of life' '* 15. Brodtkorb16 in a study of 63 institutionalized adults with epilepsy and learning disabilities found 29% to have suffered a first seizure after the age of 20. Branford et al.17, on the other hand, found in only 7% of the study population that seizures started after the age of 20. Fosgren et al. I' showed that the prevalence of epilepsy in learning disabilities remains constant for much of the period from 20-60 years.
Collacott et ~1.~ reported on a 4-year drug review programme of 215 adults with epilepsy and learning disabilities who lived in Leicestershire, UK. The review programme which occurred between 1982 and 1985 comprised all people living in institutional care. The programme achieved a reduction of polypharmacy of antiepileptic drugs, a change from the prescribing of phenobarbitone, primidone and phenytoin to carbamazepine and sodium valproate, and for some people a reduction in the frequency of seizures. For many of the 215 persons who are still alive both the medical service and the style of care will have changed significantly.
With the closure of the institutions many now live in community settings and the treatment of their epilepsy is supervised by a general practitioner and/or specialists. In addition, since 1985 four new antiepileptic drugs (vigabatrin, lamotrigine, gabapentin and topiramate) have reached the market and are indicated for people with refractory seizures.
One might expect that for the remainder of the 1982-1985 review programme cohort that: (1) more would be in remission; (2) the prescribing of phenytoin, phenobarbitone and primidone would be further reduced; and (3) the introduction of new drugs would have reduced the frequency of seizures for some. It was therefore decided to study further this cohort of individuals with learning disabilities and epilepsy 12 years after the end of the drug review programme.
In 1997, a study of all people with learning disabilities and epilepsy who live in Leicestershire was undertaken. This study included those persons who participated in the review programme of 1982-l 985 and who were still alive and living in Leicestershire. This paper presents a comparison of the epilepsy and its treatment for those people common to both the 1982-1985 programme and the 1997 study.
MATERIALS AND METHOD
Collacott et QZ.~, reported on a 4-year review of 215 people with epilepsy and learning disabilities who lived in institutional care. By the end of the review (1985) 172 people were left in the programme and information about the frequency of their seizures and use of antiepileptic drugs throughout both the review programme and the 5 years prior to the programme was noted.
In 1997, a study of epilepsy in adults with learning disabilities who lived in Leicestershire was undertaken. The study involved the completion of an extensive questionnaire by the key carers of 532 adults known to suffer both epilepsy and learning disabilities. Information gathered about each person included: demographic details; the nature of the epilepsy; the treatment of the epilepsy, including current access to services; details of the drug therapy; and the effect of epilepsy on the quality of life.
One hundred and thirty-eight adults were common to both studies and comparisons were made of their frequency of seizures and prescription of medicines.
In addition, two other comparisons were made. The first was of the 138 survivors and the 34 for whom there was no follow-up information, and the second was of the 138 of the original cohort and 172 other adults with learning disabilities and epilepsy aged over 35 years.
RESULTS
One hundred and thirty-eight adults with learning disabilities and epilepsy were common to both the review programme of 1982-1985 and the survey of 1997. Eighty (58%) were male and 58 (42%) female. Their mean age was 47 years (f12.59) and they were predominantly profoundly learning disabled (63%). Seventy-four (54%) continued to live in NHS accommodation, whilst the remaining 64 (46%) lived in community accommodation provided by a multitude of statutory, voluntary and private organizations.
Of the 138 adults, 127 (92%) were confirmed to be suffering from epilepsy. In nine cases the carers maintained that the person did not differ from epilepsy, whilst in two cases they were unsure. Tonic-clonic seizures were the most commonly reported (53%), followed by absences (3 1%) and myoclonic jerks (15%). In 47% more than one seizure type occurred.
At the end of the drug review programme (1982-1985) 33 people had not suffered a seizure for at lest 5 years (inactive epilepsy), 25 were in remission (no seizure for 3-5 years) and the remaining 80 were still suffering seizures (active epilepsy). The figures for the survey of 1997 were 27, 13 and 98, respectively (see Table 1 ). polypharmacy of antiepileptic drugs. Table 2 shows the number of antiepileptic drugs received in 1985 and 1997. The eradication of the older antiepileptic drugs (phenobarbitone, primidone and phenytoin) is an aim of most antiepileptic drug review programmes. Table 3 provides information about the use of antiepileptic drugs in 1985 and 1997.
Information was gathered about those people included in the review programme of 1982-1985 but for whom no 1997 data were available, to see if the surviving 138 persons represented a particularly refractory sample. Ninety percent had died and, if still alive in 1997, would have presented with a greater mean age (mean of 56 years vs. 47 years) than the survivors. More suffered active epilepsy at the end of the review programme of 1982-1985 (73% vs. 58%) and more received two or more antiepileptic drugs (38% vs. 22%) than the 138 people common to both time periods. In most other aspects the two groups were similar. These findings would suggest that those who had died since 1985 represented a more refractory group than the survivors.
Comparison was also made with 172 other persons with epilepsy and learning disabilities aged over 35 and living in Leicestershire. This comparison was made to see if the institutional background of the review group had in some way biased the sample. Although there were minor differences in the proportion of patients suffering particular seizure types there were no significant differences between the groups in the proportion achieving remission. The number prescribed two or more antiepileptic drugs was slightly higher (5 1% vs. 46%) for the 172 than the 138 of the review programme.
These findings would suggest that the cohort common to both time periods was not significantly different from the remainder of those with epilepsy and learning disabilities.
DISCUSSION
The findings of this follow-up study were contrary to expectation. The introduction of new therapies for the treatment of epilepsy, the expectation of continued remission from seizures and of further remission with age should have resulted in a reduction of the numbers with active epilepsy with time. In fact, the opposite has occurred. There are a number of possible explanations for the findings. The first could be that with increased age some adults with learning disabilities and epilepsy suffer a worsening of their seizure frequency. This may parallel that seen in the general population where an increased incidence of epilepsy is associated with cerebrovascular disease and degenerative neurological conditions such as Alzheimer's disease14. A second explanation could be seen as support for the need for a specialist epilepsy review clinic. During the period from 1982-1985 both epilepsy and the use of antiepileptic drugs were the focus of an expert team. This team achieved significant improvements in seizure frequency for many patients and at the same time a reduction in the polypharmacy of antiepileptic drugs. Since 1985, epilepsy has been one of a number of issues reviewed either by the general practitioners or the consultant psychiatrists specializing in learning disabilities. Branford and Co11acott'8 had noted differences in the use of antiepileptic drug treatment by patients receiving GP care rather than specialist care, but it was difficult to know if that was a factor in this study. A third explanation could be that the change to the provision of care from medical-style ward settings to small 'homely' settings in some way increased the factors which lead to a worsening of seizures.
An alternative explanation was that the cohort as a particularly refractory or unusual group. This could be somewhat discounted by the finding that many of those who had died since 1985 were those who suffered more refractory epilepsy and received more antiepileptic drugs. In addition, the performance in achieving re-
mission was almost identical in another sample of persons with epilepsy and learning disabilities who were aged over 35 years and living in Leicestershire.
Studies of mortality amongst those with learning disabilities and epilepsy "-13 show that for those with active epilepsy and frequent seizures the likelihood of premature death is high. This would increase the likelihood that those who survive are in remission and should have a greater expectation of an improvement in performance.
The introduction of new drug treatments for epilepsy does not appear to have resulted in any improvement in the overall performance. Bhaumik et al. I9 reported on a naturalistic study of the efficacy of the first three new antiepileptic drugs (vigabatrin, lamotrigine and gabapentin) on 50 adults with learning disabilities. They found the new drugs to be of limited efficacy and to cause many side effects. The introduction of the addon therapies rarely resulted in a subsequent reduction in the number of older antiepileptic drugs, the resulting effect being an increase in the number of antiepileptic drugs prescribed.
The other major changes that occurred to the prescribing of medicines were the continued reduction of the prescribing of phenobarbitone and increased prescribing of sodium valproate and carbamazepine. This change would be in line with the aims of the original review programme and constitute good medical practice.
In the 1982-1985 programme an increased mean dose for sodium valproate was noted (117 1 mg and 1516 mg). By 1997, the median dose had escalated to 2000 mg, whereas a similar increase had not occurred with carbamazepine. The reason for this could be that sodium valproate is possibly prescribed for seizures which are more refractory to treatment.
